Industry Outlook

The pharmaceutical intermediates market is set to reach from US$ 29,080.8 Mn in 2021 to US$ 41,317.4 Mn by 2030 at a compound annual growth rate (CAGR) of 4.0% during the forecast period from 2023 to 2030. Significant rise in drug formulation and research activities and supportive regulatory environment provided by global healthcare agencies will consolidate the pharmaceutical intermediates market during the forecast period.

"Significant rise in drug formulation research & development (FR&D) activities to boost the bulk intermediates market growth"

Bulk drug intermediates are reigning the product segment for pharmaceutical intermediates market. The key driver associated with its market growth is the significant rise in drug formulation research & development (FR&D).  They are used as raw material in manufacturing of bulk drugs or as a secondary product generated during the synthesis of active pharmaceutical ingredient (API) having potential to be used in various drug formulation. Custom intermediates are gaining huge traction on account of increased drug development and research activities and burgeoning requirement of novel medicines to treat orphan diseases.

"Rising prevalence of life-threatening diseases and stringent regulatory norms imposed by healthcare agencies worldwide propel the pharmaceutical & biotechnology companies worldwide"

Pharmaceutical & biotechnology companies are spearheading the end-user segment for pharmaceutical intermediates market. The key drivers associated with its dominating market growth are rising prevalence of life-threatening diseases and stringent regulatory norms pertaining to cGMP and cGLP guidelines for drug manufacturing imposed by healthcare agencies worldwide. Research laboratories have shown impressive growth in the last 2 decades on account of increasing demand for pharmaceutical intermediates in developing novel medicines for treating rare and autoimmune diseases. Contract manufacturing organization will be highlighting rampant growth during the forecast period on account of increasing demand for generic medicines due to patent expiration of blockbuster drugs in the near future and significant rise in drug manufacturing outsourcing activities to penetrate untapped market worldwide.

"Presence of well-developed healthcare infrastructure and rising public health awareness together drive the market growth in North America"

North America presently holds 35.8% market growth and is the largest regional segment for pharmaceutical intermediates market. The drivers responsible for its positive market growth are presence of well developed healthcare infrastructure and rising public health awareness. Europe is placed second I the regional segment representing 30.4% market share on account of significant rise in patient population seeking medical intervention for life threatening diseases and supportive regulatory environment provided by European Medical Agency (EMA) for pharmaceutical intermediates market. Asia Pacific is accountable for 20.2% market share owing to proactive government policies resulting in flourishing drug manufacturing activities and serves as a lucrative market opportunity for western giants to enter into strategic collaboration and agreement with local players owing to the flourishing generic drug market in Asia Pacific region.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Pharmaceutical Intermediates market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Pharmaceutical Intermediates market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Pharmaceutical Intermediates market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Pharmaceutical Intermediates market?
• Which is the largest regional market for Pharmaceutical Intermediates market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Pharmaceutical Intermediates market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Pharmaceutical Intermediates market worldwide?